Our Pricing

Saxenda vs Wegovy: Expert UK Pharmacist Comparison

Published on: June 03, 2026

When evaluating a saxenda vs wegovy uk comparison, understanding the clinical differences between liraglutide and semaglutide is essential for making an informed choice. At Cured Pharmacy, our UK-registered clinical team has guided thousands of patients through this decision, and we provide transparent upfront pricing with Wegovy available from £79.00. Both medications are MHRA-licensed prescription treatments that require clinical assessment by a UK prescriber before dispensing.

Saxenda vs Wegovy: How They Work Differently

Saxenda contains liraglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to regulate appetite and slow gastric emptying [1]. It requires daily subcutaneous injection and has been licensed in the UK since 2015 for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities.

Wegovy contains semaglutide, a longer-acting GLP-1 receptor agonist that offers once-weekly dosing rather than daily injections [2]. The extended half-life of semaglutide allows for sustained appetite suppression throughout the week, which many patients find more convenient. Both medications work by reducing hunger signals, increasing feelings of fullness, and slowing the rate at which food leaves the stomach.

The key pharmacological difference lies in their binding affinity and duration of action. Semaglutide demonstrates stronger GLP-1 receptor binding and a longer elimination half-life of approximately 7 days compared to liraglutide's 13 hours [2]. This translates to once-weekly versus daily administration, which significantly impacts treatment adherence and patient satisfaction.

Clinical Trial Results: Saxenda vs Wegovy Efficacy

In the SCALE Obesity and Prediabetes trial, patients using Saxenda achieved an average weight loss of 8.0% of their initial body weight over 56 weeks, compared to 2.6% in the placebo group [1]. Approximately 63.2% of patients on liraglutide lost at least 5% of their body weight, whilst 33.1% achieved losses of 10% or more.

The STEP 1 trial for Wegovy demonstrated substantially higher efficacy, with participants losing an average of 14.9% of their initial body weight over 68 weeks, compared to 2.4% with placebo [2]. Notably, 86.4% of semaglutide-treated patients achieved at least 5% weight loss, and 69.1% lost 10% or more of their starting weight. These results represent approximately double the weight reduction seen with liraglutide in head-to-head comparisons.

Direct comparison studies confirm semaglutide's superior efficacy. In the STEP 8 trial, which directly compared once-weekly semaglutide to daily liraglutide, semaglutide produced a mean weight loss of 15.8% versus 6.4% with liraglutide over 68 weeks [3]. This clinically significant difference makes Wegovy the more effective option for patients seeking maximum weight reduction, subject to prescriber assessment of individual suitability.

Real-World Effectiveness Beyond Clinical Trials

Our experience at Cured Pharmacy aligns with published trial data. Superintendent Pharmacist Tarun Kumar (GPhC 2233073) notes that patients transitioning from Saxenda to Wegovy often report enhanced appetite suppression and accelerated weight loss, though individual responses vary considerably. The once-weekly dosing schedule of Wegovy also improves adherence rates, as patients find it easier to maintain their treatment regimen without daily injections.

Saxenda vs Wegovy: Dosing and Administration

Saxenda requires daily subcutaneous injection, starting at 0.6 mg and gradually increasing over five weeks to the maintenance dose of 3.0 mg daily [1]. This dose escalation helps minimise gastrointestinal side effects whilst allowing the body to adjust to the medication. Patients must inject Saxenda at approximately the same time each day, which requires consistent daily commitment.

Wegovy follows a monthly dose escalation schedule, starting at 0.25 mg once weekly and increasing every four weeks until reaching the maintenance dose of 2.4 mg weekly [2]. The injection can be administered on any day of the week, though patients should maintain the same day each week. This once-weekly schedule significantly reduces the treatment burden compared to daily injections.

Both medications are administered via pre-filled, disposable injection pens designed for subcutaneous injection into the abdomen, thigh, or upper arm. The injection technique is identical for both treatments, and our clinical team provides comprehensive injection training during your consultation. Patients typically find the once-weekly Wegovy regimen easier to integrate into their lifestyle, though some prefer the daily routine of Saxenda for maintaining consistent focus on their weight management goals.

Side Effects: What to Expect with Each Treatment

Both Saxenda and Wegovy share a similar side effect profile, as they belong to the same medication class. The most common adverse effects are gastrointestinal in nature, including nausea, diarrhoea, constipation, vomiting, and abdominal discomfort [1][2]. These symptoms typically occur during dose escalation and often diminish as the body adapts to treatment.

In clinical trials, nausea affected approximately 39.3% of Saxenda users and 44.2% of Wegovy users, making it the most frequently reported side effect for both medications [1][2]. Vomiting occurred in 15.7% of liraglutide patients versus 24.8% of semaglutide patients. The higher incidence with Wegovy may relate to its stronger GLP-1 receptor activation, though the once-weekly dosing means patients experience side effects less frequently throughout the week.

Serious but rare side effects include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans) [2][3]. Both medications carry a boxed warning regarding thyroid tumours and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will assess these risk factors during your clinical consultation before prescribing either treatment.

Managing Side Effects Effectively

Our clinical team recommends several strategies to minimise gastrointestinal symptoms: eating smaller, more frequent meals; avoiding high-fat foods; staying well-hydrated; and not lying down immediately after eating. If side effects become intolerable, your prescriber may adjust the dose escalation schedule or consider switching between treatments. Most patients find that symptoms improve significantly after the first 4-8 weeks of treatment.

Saxenda vs Wegovy UK: Cost and Value Comparison

At Cured Pharmacy, Wegovy is available from £79.00, representing exceptional value for a once-weekly GLP-1 treatment with superior clinical efficacy. Pricing varies based on the prescribed dose strength, which your UK prescriber determines following clinical assessment. We guarantee the lowest prices in the UK market and display all costs transparently before you complete your consultation.

When comparing cost-effectiveness, Wegovy offers better value despite potentially higher per-pen pricing at some pharmacies. The once-weekly dosing means you use approximately 4 pens per month, whilst Saxenda's daily injections require 30 individual doses monthly. More importantly, the significantly greater weight loss achieved with semaglutide means patients may reach their target weight faster, potentially reducing the total treatment duration and overall cost.

Both treatments are currently not routinely available on NHS prescription for weight management alone, though this may be changing as NICE guidelines evolve. Private prescription remains the primary access route for most UK patients. At Cured Pharmacy, our transparent pricing model ensures you know the exact cost before proceeding with your consultation, with no hidden fees or surprise charges at checkout.

Which Treatment Is Right for You: Saxenda vs Wegovy?

Choosing between Saxenda and Wegovy depends on multiple factors including your weight loss goals, lifestyle preferences, budget, and medical history. Wegovy generally represents the superior choice for patients seeking maximum weight reduction, with clinical trials demonstrating approximately double the efficacy of Saxenda [3]. The once-weekly dosing also offers greater convenience and improved adherence for most patients.

Saxenda may be appropriate for patients who prefer daily dosing to maintain consistent focus on their weight management programme, those who have previously responded well to liraglutide, or individuals with specific medical considerations that make semaglutide less suitable. Some patients also find that starting with Saxenda and later transitioning to Wegovy provides a gentler introduction to GLP-1 therapy, though this approach should be discussed with your prescriber.

At Cured Pharmacy, your UK-registered prescriber will conduct a comprehensive clinical assessment considering your BMI, weight-related comorbidities, previous weight loss attempts, medication history, and personal preferences. This consultation takes under 3 minutes to complete online and ensures you receive the most appropriate treatment for your individual circumstances. Both medications require ongoing medical supervision, and your prescriber will schedule regular reviews to monitor your progress and adjust treatment as needed.

Starting Your Weight Loss Journey at Cured Pharmacy

Beginning treatment is straightforward: complete our free online consultation, receive a clinical decision from a UK prescriber within hours, and have your medication dispensed by our GPhC-registered pharmacy (9012511) with discreet next-day delivery. We only supply genuine UK-licensed medications, and our clinical team remains available throughout your treatment journey to answer questions and provide support. Start your assessment today to discover which treatment offers the best solution for your weight management goals.

Scientific References

1. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Rubino, D., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, diet, and physical activity.